Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID)
This study has been completed.
First Received: October 16, 2005   Last Updated: March 25, 2009   History of Changes
Sponsor: AstraZeneca
Information provided by: AstraZeneca
ClinicalTrials.gov Identifier: NCT00240318
  Purpose

The purpose of this study is to see if 40 mg of rosuvastatin taken daily will reduce the atherosclerosis (fatty deposits) in your arteries


Condition Intervention Phase
Coronary Arteriosclerosis
Drug: Rosuvastatin calcium
Phase III

Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Official Title: A 104-Week, Open-Label, Multi-Centre, Phase IIIb Study Evaluating the Effect of Treatment With Rosuvastatin 40 mg on Atherosclerotic Disease as Measured by Intravascular Ultrasound and Quantitative Coronary Angiography in Subjects Undergoing Coronary Angiography Who Have Coronary Artery Disease

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • to evaluate whether 2 years of treatment with 40 mg rosuvastatin results in regression of coronary artery atheroma burden via the total atheroma volume in the most diseased segment or the percent atheroma volume, as measured by IVUS

Secondary Outcome Measures:
  • to evaluate whether treatment with rosuvastatin results in:
  • Regression of coronary artery atheroma burden, as assessed by TAV
  • Regression of coronary artery disease as measured by quantitative coronary angiography (QCA).
  • To evaluate the change in lipid and lipoprotein levels as assessed by percentage change from baseline.
  • To evaluate the safety of rosuvastatin

Estimated Enrollment: 450
Study Start Date: November 2002
Study Completion Date: November 2005
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical indication for coronary catheterization. Target Coronary Artery: The target vessel must have .50% reduction in lumen diameter by angiographic visual estimation throughout a segment of at least 40 mm in length (the target segment) and the vessel must be large enough to accommodate the IVUS catheter. A lesion of up to 60% is permitted distal to the target segment. Side branches of the target (imaged) vessel may be narrowed up to 70% by visual estimation, provided the target segment contains no lesion greater than 50%.

Exclusion Criteria:

Use of lipid-lowering medication for more than 3 months within the previous 12 months. Longer periods of treatment are not permitted because of the potential effects of such therapy on coronary atherosclerosis. Subjects receiving treatment with a lipid-lowering medication within the past 4 weeks require a 4-week wash-out period following which a baseline lipid profile will be taken at visit 2.

Clinically significant heart disease which, in the opinion of the Principal Investigator (or designee), is likely to require coronary bypass surgery, cardiac transplantation, surgical repair and/or replacement during the course of the study.

-

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00240318

  Hide Study Locations
Locations
United States, Alabama
Research Site
Birmingham, Alabama, United States
United States, California
Research Site
Los Angeles, California, United States
Research Site
San Francisco, California, United States
Research Site
Santa Rosa, California, United States
Research Site
Stockton, California, United States
United States, Colorado
Research Site
Denver, Colorado, United States
United States, Connecticut
Research Site
Hartford, Connecticut, United States
United States, Florida
Research Site
Atlantis, Florida, United States
United States, Illinois
Research Site
Chicago, Illinois, United States
Research Site
Maywood, Illinois, United States
United States, Maine
Research Site
Auburn, Maine, United States
United States, Maryland
Research Site
Baltimore, Maryland, United States
United States, Michigan
Research Site
Ann Arbor, Michigan, United States
Research Site
Petoskey, Michigan, United States
United States, Minnesota
Research Site
Minneapolis, Minnesota, United States
Research Site
St. Paul, Minnesota, United States
United States, New York
Research Site
Buffalo, New York, United States
Research Site
Valhalla, New York, United States
Research Site
Williamsville, New York, United States
United States, North Carolina
Research Site
Chapel Hill, North Carolina, United States
United States, Ohio
Research Site
Toledo, Ohio, United States
United States, Pennsylvania
Research Site
Danville, Pennsylvania, United States
United States, Texas
Research Site
Houston, Texas, United States
United States, Wisconsin
Research Site
Milwaukee, Wisconsin, United States
Australia
Research Site
Auchenflower, Australia
Research Site
Clayton, Australia
Research Site
Heidelberg, Australia
Research Site
New Lambton, Australia
Belgium
Research Site
Aalst, Belgium
Research Site
Bruxelles, Belgium
Research Site
Edegem, Belgium
Research Site
Liege, Belgium
Canada, Nova Scotia
Research Site
Halifax, Nova Scotia, Canada
Canada, Quebec
Research Site
Montreal, Quebec, Canada
Research Site
Ste-Foy, Quebec, Canada
France
Research Site
Massy, France
Research Site
Limoges, France
Research Site
Lyon, France
Research Site
Creteil, France
Research Site
Melun, France
Research Site
Paris, France
Research Site
Pessac, France
Research Site
Toulouse, France
Italy
Research Site
Pisa, Italy
Research Site
Milan, Italy
Research Site
Pavia, Italy
Research Site
Genova, Italy
Research Site
Rome, Italy
Research Site
Rome, Italy
Research Site
Siena, Italy
Research Site
Udine, Italy
Italy, Milan
Research Site
Rozzano, Milan, Italy
Italy, Venezia
Research Site
Mirano, Venezia, Italy
Netherlands
Research Site
Amsterdam, Netherlands
Research Site
Maastricht, Netherlands
Research Site
Nieuwegein, Netherlands
Research Site
Zwolle, Netherlands
Spain
Research Site
Barcelona, Spain
Research Site
Madrid, Spain
Research Site
Valladolid, Spain
Research Site
Murias, Spain
Research Site
Malaga, Spain
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: AstraZeneca Crestor Medical Sciences Director, MD AstraZeneca
  More Information

Additional Information:
Publications:
Study ID Numbers: D3562C00076
Study First Received: October 16, 2005
Last Updated: March 25, 2009
ClinicalTrials.gov Identifier: NCT00240318     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by AstraZeneca:
Coronary Artery Disease

Additional relevant MeSH terms:
Arterial Occlusive Diseases
Antimetabolites
Heart Diseases
Molecular Mechanisms of Pharmacological Action
Myocardial Ischemia
Antilipemic Agents
Vascular Diseases
Enzyme Inhibitors
Arteriosclerosis
Anticholesteremic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pharmacologic Actions
Coronary Disease
Rosuvastatin
Therapeutic Uses
Cardiovascular Diseases
Coronary Artery Disease

ClinicalTrials.gov processed this record on November 20, 2009